Sign Up

AUGE

DE:AUGENAERZTE-HEILIGENGEIST

Augenärzte Heiligengeist

  • Privately Held
OverviewAnalysisMetricsFinancialsFilingsAPIData

Company Overview

Metric
Company NameAugenärzte HeiligengeistAugenärzte am TheaterwallAugenärzte Heiligengeist
Symbol
MSH IDDE:AUGENAERZTE-HEILIGENGEISTDE:AUGENAERZTE-AM-THEATERWALLDE:AUGENAERZTE-HEILIGENGEIST
MarketPRIVATEPRIVATEPRIVATE
SectorHealthcare & Health ServicesHealthcare & Health ServicesHealthcare & Health Services
IndustryHealthcareMedical ServicesHealthcare
CountryDEDEDE
Stage
Employee Count
Websiteaugenaerzte-heiligengeist.deaugenaerzte-am-theaterwall.deaugenaerzte-heiligengeist.de
LinkedIn
Founders

Market Metrics

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Financial Performance

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

Valuation Multiples

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Operational Metrics

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Cash Flow Metrics

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Balance Sheet Metrics

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue